HSCSHealthcare · Medical DevicesThe 1 Wall Street analysts covering HeartSciences, Inc. hold a median 12-month price target of $12 — +232.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 28 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores HeartSciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (3): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on HSCS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +232.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Mar 2026 | Ascendiant Capital | Maintains | Buy | $9.20 → $8.00 |
| 22 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 1 Oct 2025 | Ascendiant Capital | Maintains | Buy | — |
| 18 Mar 2025 | Ascendiant Capital | Maintains | Buy | — |
| 18 Dec 2024 | Maxim Group | Reiterates | Buy | — |
| 23 Sept 2024 | Ascendiant Capital | Reiterates | Buy | — |
| 30 Jan 2023 | Ascendiant Capital | Initiates | Buy | — |
| 19 Dec 2022 | Maxim Group | Maintains | Buy | — |
| 9 Nov 2022 | Maxim Group | Initiates | Buy | — |
| 8 Aug 2022 | Benchmark | Initiates | Speculative Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
HSCS appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, HeartSciences, Inc. returned +21.5% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 71% of US stocks
Cheaper than 1% of US stocks
Cheaper than 2% of US stocks
Cheaper than 74% of US stocks
Higher than 54% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 97% of US stocks
Higher than 1% of US stocks
Higher than 2% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
HeartSciences, Inc. has a market value of $16.3M and an enterprise value of $20.2M.
Revenue in the twelve months to 30 Apr 2026: $4K. The latest quarter grew 10.5% year on year.
Net income over the same four quarters: −$9.1M, a −211666.5% net margin.
Free cash flow in the twelve months to 30 Apr 2026: −$7.5M.
Trailing P/E: 0.5×; forward P/E: −1.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
HeartSciences, Inc. employs 14 people — $308.5 of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own HeartSciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research compares HeartSciences (HSCS) and ImmunityBio (IBRX) with their sector based on performance so far this year. The excerpt does not provide performance results.
Why it matters — HSCS watchers may find the year-to-date peer and sector comparison relevant, though the excerpt gives no results or ranking.
HeartSciences filed a definitive proxy statement with the SEC for its proposed business combination with Fortitude Mining. The company’s board unanimously recommends shareholders vote for the transaction-related proposals; the combination remains subject to shareholder approval and other closing conditions.
Why it matters — The filing marks a milestone in the proposed transaction, which is expected to establish a publicly traded digital asset mining platform focused on Zcash if completed.
HeartSciences announced that the FDA granted 510(k) clearance (K260005) for its MyoVista wavECG device as a 12-lead resting electrocardiograph. The clearance covers ECG signal acquisition and interpretation for adult and pediatric patients in hospitals and healthcare facilities, with interpretive statements provided to clinicians on an advisory basis.
Why it matters — The clearance is a regulatory milestone for HSCS’s MyoVista wavECG device and specifies its permitted patient settings and advisory interpretation use.
Fortitude Mining Holdings announced the appointment of Kimberly Pittman as Chief Legal Officer, effective September 28. Pittman joins Fortitude's executive leadership team as the company prepares for its previously announced proposed business combination with HeartSciences Inc. (Nasdaq: HSCS).
Why it matters — HSCS watchers would care because Pittman's appointment signals Fortitude is advancing its executive leadership in preparation for the proposed business combination with HeartSciences.
HeartSciences reported its fiscal first quarter 2027 financial results and provided a business update. The company noted that its proposed business combination with Fortitude, a Zcash-anchored digital asset mining platform, continues to progress with closing expected in Q4 calendar 2026.
Why it matters — HSCS watchers would want to track the timeline and progress of the proposed Fortitude business combination, which is expected to close in Q4 calendar 2026.
The 1 Wall Street analysts covering HeartSciences, Inc. have a median 12-month price target of $12, with estimates ranging from $12 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering HeartSciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks HeartSciences, Inc. 47 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, HeartSciences, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +232.4% from the last close, and Ticker Nerd's factor model ranks HeartSciences, Inc. 47 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering HeartSciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HSCS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.
HeartSciences, Inc. returned +21.5% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
HeartSciences Inc. is a medical technology company focused on artificial intelligence-enhanced electrocardiography.
The most recent item we track (Zacks Investment Research, 22 Oct 2026): "Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year?". Zacks Investment Research compares HeartSciences (HSCS) and ImmunityBio (IBRX) with their sector based on performance so far this year. The excerpt does not provide performance results.
HeartSciences Inc. is a medical technology company focused on artificial intelligence-enhanced electrocardiography. The company develops AI-ECG solutions designed to improve the clinical usefulness of standard ECG testing by helping detect cardiac dysfunction and related heart conditions earlier in care pathways. Its current product set includes the MyoVista wavECG device, a resting 12-lead ECG that combines conventional rhythm and diagnostic information in a single test, and MyoVista Insights, a cloud-native ECG management platform that is designed to work across different device and vendor environments. HeartSciences serves healthcare settings where rapid cardiac screening and interpretation are important, including frontline and point-of-care environments. Founded in 2007 and headquartered in Southlake, Texas, the company positions itself within the healthcare information technology and medical devices market, with a focus on practical ECG enhancement rather than replacing existing clinical workflows.
CEO Mr. Andrew Simpson · 14 employees · United States · https://heartsciences.com
